The increasing global threat of antimicrobial resistance will be a key focus at this year’s conference. Other topics include the commercial and scientific issues in manufacturing, clinical trials, regulation, immune profiling and human vaccines including influenza, and therapeutic and emerging disease vaccines.

Gabrielle joins the panel discussion: ‘Harmonising priorities in Europe: Role of public health, government strategies and industry to halting the AMR crisis – do we have a consistent message?’ The panel will explore how regulatory and access policies can be used to strengthen utilisation of vaccines in our international action plans to address AMR.

Vaccines have the potential to play a significant role in helping to alleviate the problem of drug resistance. In addition to guarding against major diseases such as tuberculosis and malaria, and preventing viral infections for which antibiotics are often wrongly prescribed, they also reduce the need to use antibiotics. By limiting the use of antimicrobial medicines, they can, in turn, slow or curtail the emergence of resistance.

Gabrielle will share insights from the Antimicrobial Resistance Benchmark which tracks the pharmaceutical industry’s response to AMR. The Benchmark evaluates 30 companies in their actions to bring AMR under control, and covers R&D, responsible manufacturing, access and stewardship. Take a look at the findings from the first Antimicrobial Resistance Benchmark released in 2018.